News for Harrow Health, Inc. (HROW)

Harrow Health's Q3 financial results show a miss on earnings and revenue, but with positive trends in prescriptions and demand, leading to stock price...

Harrow secures Medicare coverage for dry eye treatment VEVYE

Harrow Health stock set for gains as TRIESENCE and MELT-300 drive growth, says B.Riley

HROW stock hits 52-week high at $38.48 amid robust growth

Earnings call: Harrow Health reports record revenue, bullish on VEVYE growth

Harrow Health shares target raised by Craig-Hallum on positive script trends

Earnings call: Harrow Health reports record revenues, optimistic outlook

U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday.

The market has been driven by the increasing prevalence of retinal illnesses worldwide and the demand for effective and economical treatment options. For...

Harrow has two outstanding notes on offer that come up for maturity in 2026 and 2027. Find out why commons are a Hold with HROWM a Buy.

Harrow Health is a well-managed ophthalmic medicines business and has remained profitable for a number of years. Read why HROW stock is a Buy.

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

SRK Fund I declined -9.41% during 2H 2021 and or the year, the Fund appreciated 46.71%. Click here to read the full fund letter.

Harrow Health, Inc. HROW, an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd.